Connection

Raymond Anton to Naltrexone

Back to Details
This is a "connection" page, showing publications Raymond Anton has written about Naltrexone.
Raymond Anton
Connection Strength
8.714
Naltrexone
  1. Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial. Pharmacogenomics J. 2022 02; 22(1):1-8.
    View in: PubMed
    Score: 0.716
  2. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial. Alcohol Clin Exp Res. 2020 10; 44(10):2084-2096.
    View in: PubMed
    Score: 0.673
  3. Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence. Alcohol Clin Exp Res. 2018 Apr; 42(4):751-760.
    View in: PubMed
    Score: 0.562
  4. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status. Neuropsychopharmacology. 2017 Dec; 42(13):2640-2653.
    View in: PubMed
    Score: 0.531
  5. Commentary on Subbaraman et al. (2013) [corrected]: cravings as a mediator and moderator of drinking outcomes in the COMBINE Study. Addiction. 2013 Oct; 108(10):1745-6.
    View in: PubMed
    Score: 0.415
  6. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. Alcohol Clin Exp Res. 2012 Nov; 36(11):2000-7.
    View in: PubMed
    Score: 0.377
  7. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry. 2011 Jul; 168(7):709-17.
    View in: PubMed
    Score: 0.349
  8. Naltrexone for the management of alcohol dependence. N Engl J Med. 2008 Aug 14; 359(7):715-21.
    View in: PubMed
    Score: 0.291
  9. Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence. Pharmacogenomics. 2008 Jun; 9(6):655-8.
    View in: PubMed
    Score: 0.287
  10. Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist? Alcohol Clin Exp Res. 2008 May; 32(5):771-6.
    View in: PubMed
    Score: 0.283
  11. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb; 65(2):135-44.
    View in: PubMed
    Score: 0.281
  12. What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res. 2007 Apr; 31(4):596-603.
    View in: PubMed
    Score: 0.265
  13. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006 May 03; 295(17):2003-17.
    View in: PubMed
    Score: 0.249
  14. Naltrexone treatment of adolescent alcoholics: an open-label pilot study. J Child Adolesc Psychopharmacol. 2005 Oct; 15(5):723-8.
    View in: PubMed
    Score: 0.239
  15. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol. 2005 Aug; 25(4):349-57.
    View in: PubMed
    Score: 0.236
  16. Effectiveness of naltrexone in a community treatment program. Alcohol Clin Exp Res. 2004 Nov; 28(11):1710-7.
    View in: PubMed
    Score: 0.224
  17. Recent advances in the pharmacotherapy of alcoholism. Curr Psychiatry Rep. 2004 Oct; 6(5):332-8.
    View in: PubMed
    Score: 0.223
  18. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol. 2004 Aug; 24(4):421-8.
    View in: PubMed
    Score: 0.220
  19. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl). 2004 Apr; 173(1-2):32-40.
    View in: PubMed
    Score: 0.212
  20. Current pharmacotherapies of alcoholism: a U.S. perspective. Am J Addict. 2003; 12(s1):s53-s68.
    View in: PubMed
    Score: 0.197
  21. Naltrexone for alcohol dependence: comments on Morris et al. (2001). Addiction. 2001 Dec; 96(12):1855.
    View in: PubMed
    Score: 0.183
  22. World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom. Addiction. 2020 09; 115(9):1668-1680.
    View in: PubMed
    Score: 0.162
  23. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction. 2020 08; 115(8):1426-1437.
    View in: PubMed
    Score: 0.161
  24. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999 Nov; 156(11):1758-64.
    View in: PubMed
    Score: 0.158
  25. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials. JAMA Psychiatry. 2019 04 01; 76(4):374-381.
    View in: PubMed
    Score: 0.152
  26. Pharmacologic treatment of alcoholism. Handb Clin Neurol. 2014; 125:527-42.
    View in: PubMed
    Score: 0.106
  27. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol. 2013 Nov; 18(6):937-46.
    View in: PubMed
    Score: 0.098
  28. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacology. 2013 Feb; 38(3):414-22.
    View in: PubMed
    Score: 0.097
  29. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res. 2009 Mar; 33(3):383-93.
    View in: PubMed
    Score: 0.074
  30. Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry. 2008 Apr; 65(4):466-75.
    View in: PubMed
    Score: 0.071
  31. The impact of alcohol dependence and posttraumatic stress disorder on cold pressor task response. J Stud Alcohol. 2006 Sep; 67(5):700-6.
    View in: PubMed
    Score: 0.064
  32. COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms. J Stud Alcohol Suppl. 2005 Jul; (15):56-64; discussion 33.
    View in: PubMed
    Score: 0.059
  33. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res. 2004 Sep; 28(9):1362-70.
    View in: PubMed
    Score: 0.055
  34. A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology. 2003 Apr; 28(4):755-64.
    View in: PubMed
    Score: 0.049
  35. Multiple family therapy and naltrexone in the treatment of opiate dependence. Drug Alcohol Depend. 1981 Sep; 8(2):157-68.
    View in: PubMed
    Score: 0.045
  36. Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. Neuropsychopharmacology. 2021 11; 46(12):2132-2139.
    View in: PubMed
    Score: 0.045
  37. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000 Nov-Dec; 35(6):587-93.
    View in: PubMed
    Score: 0.042
  38. Drinking in alcoholics following an alcohol challenge research protocol. J Stud Alcohol. 2000 Mar; 61(2):220-4.
    View in: PubMed
    Score: 0.041
  39. Contribution of carbohydrate deficient transferrin to gamma glutamyl transpeptidase in evaluating progress of patients in treatment for alcoholism. Alcohol Clin Exp Res. 1999 Jan; 23(1):115-20.
    View in: PubMed
    Score: 0.037
  40. Pharmacotherapy of alcoholism--10 years of progress. Alcohol Clin Exp Res. 1996 Nov; 20(8 Suppl):172A-175A.
    View in: PubMed
    Score: 0.032
  41. Association between a brief alcohol craving measure and drinking in the following week. Addiction. 2016 06; 111(6):1004-10.
    View in: PubMed
    Score: 0.031
  42. The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry. 1996 Mar; 53(3):225-31.
    View in: PubMed
    Score: 0.031
  43. Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions. Alcohol Alcohol Suppl. 1996 Mar; 31(1):43-53.
    View in: PubMed
    Score: 0.031
  44. Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials. J Stud Alcohol Drugs. 2014 Mar; 75(2):335-46.
    View in: PubMed
    Score: 0.027
  45. Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study. Drug Alcohol Depend. 2013 Sep 01; 132(1-2):244-50.
    View in: PubMed
    Score: 0.025
  46. Factor structure and predictive validity of the Obsessive Compulsive Drinking Scale. Alcohol Clin Exp Res. 1999 Sep; 23(9):1484-91.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.